Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Emapalumab[1] Emapalumab[1] Emapalumab 💬 [1] IFNG 💬 [32] African trypanosomiasis, Allograft rejection, Amoebiasis, Antigen processing and presentation, Chagas disease, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hepatitis C, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Leishmaniasis, Malaria, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Proteasome, Rheumatoid arthritis, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬[3] 49, 65, 107 💬
2Emapalumab-Izsg[1] Emapalumab[1] Emapalumab 💬 [1] IFNG 💬 [32] African trypanosomiasis, Allograft rejection, Amoebiasis, Antigen processing and presentation, Chagas disease, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hepatitis C, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Leishmaniasis, Malaria, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Proteasome, Rheumatoid arthritis, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬[1] 65 💬